PMID-28976144 – Immunoprotective Activity of Peptides in Spleen During Aging

PMID-28976144 – Immunoprotective Activity of Peptides in Spleen During Aging

Khavinson VKh, Linkova NS, Dyatlova AS. [Molecular aspects of immunoprotective activity of peptides in spleen during the ageing process]. Adv Gerontol. 2017;30(3):371-376.

Quick Reference

Property Value
PMID 28976144
DOI
Year 2017
Journal Advances in Gerontology (Uspekhi Gerontologii)
Study Type In vitro / Animal in vivo
Evidence Level V
Sample Aging rat spleen tissue and cell cultures
Peptide(s) Studied Crystagen, Vilon

Key Findings

  • Crystagen (Glu-Asp-Pro) demonstrated immunoprotective effects in spleen tissue during aging
  • Crystagen activated B-cells but had a greater effect on T-cell immunity (increased CD3+, CD4+ cells; normalized CD4+/CD8+ ratio)
  • The peptide did not cause significant cell renewal in aged spleen but rather modulated existing immune cell function
  • Vilon (Lys-Glu) showed complementary immunomodulatory activity
  • The immunoprotective effect was attributed to peptide-mediated gene expression changes in immune cells

Study Design

Mixed in vitro/in vivo study examining the effects of short peptide bioregulators on spleen immune function during aging. Included both tissue culture experiments and assessment of splenic immune cell populations in aging rats.

Limitations

  • Published in Russian-language journal (English abstract only)
  • Limited description of methodology in English abstract
  • All authors from the Khavinson group
  • No independent replication
  • The distinction between Crystagen's T-cell vs. B-cell effects needs independent confirmation

Clinical Relevance

Provides preclinical evidence for Crystagen's immune-supportive properties in aging. The T-cell predominant effect is relevant to age-related immunosenescence, but clinical validation is absent.

Methodological Note: This study originates from the Khavinson bioregulation group. Independent replication by Western laboratories is lacking.

Related

#research #animal-in-vivo #in-vitro #evidence-level-V #khavinson-bioregulator #peptide-crystagen